We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01400633
Recruitment Status : Completed
First Posted : July 22, 2011
Last Update Posted : May 25, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to investigate the overall response rate (ORR) and safety when treating patients with myelodysplastic syndrome with decitabine. Decitabine is to be administered as long as there is evidence of clinical benefit.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Drug: decitabine injection Phase 4

Detailed Description:
This study is a prospective (the study follows a group of individuals over time), open label (all people involved know the identity of the intervention), multicenter, single arm (one group of patients receiving the same treatment), observational study to observe the response rate and safety of decitabine when treating patients with myelodysplastic syndrome with decitabine. Decitabine is to be administered as long as there is evidence of clinical benefit. It will be assessed if the treatment duration could be prolonged by appropriate toxicity management such as an active antibiotic prophylaxis or dose and schedule modification, and whether this leads to potentially increased clinical benefits such as higher response rate, longer time to Acute Myeloid Leukemia, and prolonged overall survival. For safety evaluation, adverse events and peripheral blood findings will be collected. The patient will receive decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks.

Study Design

Study Type : Observational
Actual Enrollment : 156 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective Multicenter Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome
Study Start Date : December 2010
Primary Completion Date : March 2014
Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Decitabine
U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
001
decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
Drug: decitabine injection
decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks


Outcome Measures

Primary Outcome Measures :
  1. overall response rate [ Time Frame: every 28 days up to approximately 5 years ]

Secondary Outcome Measures :
  1. The change of transfusion requirements [ Time Frame: every 4 weeks up to approximately 5 years ]
  2. Overall survival [ Time Frame: every 3 months up to approximately 5 years ]
  3. Adverse events [ Time Frame: every 4 weeks up to approximately 5 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Secondary or tertiary hospitals in South Korea
Criteria

Inclusion Criteria:

  • Patients diagnosed with (primary or secondary) Myelodysplastic Syndrome including Chronic Myelomonocytic Leukemia (CMML)
  • Patients with an International Prognostic Scoring System >= Int-1
  • Patients who were never treated with hypomethylating agent (azacitidine and decitabine)
  • Female patients who are postmenopausal or received contraceptive operation or refrain from sexual relations. Women of childbearing potential should conduct an effective method of birth control (oral contraceptives, injections, intrauterine device, double barrier method, contraceptive patch and male partner's sterilization), in case of male patients who will not have a baby within 2 months after the completion of decitabine therapy
  • Patients who signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

  • Patients diagnosed with Acute Myelogenous Leukemia (AML, bone marrow stem cell counts exceeding 20%) or other progressive malignant diseases
  • Patients with active infection of virus or bacteria
  • Patients who used to be treated with azacitidine or decitabine
  • Patients who are hypersensitive to excipients of decitabine
  • Patients who are pregnant or breast-feeding.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01400633


Locations
Korea, Republic of
Ansan, Korea, Republic of
Anyang, Korea, Republic of
Busan, Korea, Republic of
Cheonan, Korea, Republic of
Chungcheongbuk-Do, Korea, Republic of
Chungnam, Korea, Republic of
Daegu, Korea, Republic of
Daejeon, Korea, Republic of
Gyeonggi-Do, Korea, Republic of
Hwasun Gun, Korea, Republic of
Incheon, Korea, Republic of
Jinju-Si, Korea, Republic of
Kwanju, Korea, Republic of
Pusan, Korea, Republic of
Seoul, Korea, Republic of
Suwon, Korea, Republic of
Sponsors and Collaborators
Janssen Korea, Ltd., Korea
Investigators
Study Director: Janssen Korea, Ltd. Clinical Trial Janssen Korea, Ltd.
More Information

Responsible Party: Janssen Korea, Ltd., Korea
ClinicalTrials.gov Identifier: NCT01400633     History of Changes
Other Study ID Numbers: CR017842
DACOGENMDS4013 ( Other Identifier: Janssen Korea, Ltd., Korea )
Long-term treatment of Dacogen ( Other Identifier: Janssen Korea, Ltd., Korea )
First Posted: July 22, 2011    Key Record Dates
Last Update Posted: May 25, 2015
Last Verified: May 2015

Keywords provided by Janssen Korea, Ltd., Korea:
Myelodysplastic Syndrome
Dacogen
decitabine
epigenetic therapy
hypomethylating agent

Additional relevant MeSH terms:
Syndrome
Myelodysplastic Syndromes
Preleukemia
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Decitabine
Azacitidine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors